NY S04447

Allows pharmacists to substitute brand name epinephrine auto-injectors with alternate versions containing the same active ingredients, dosage form, and strength, regardless of FDA interchangeability status.

Substitution is permitted only when the prescriber does not mark the prescription "as written" and the alternate auto-injector costs less than the brand name product.

Requires pharmacists to inform patients of the alternate option and obtain consent before dispensing the substitute product.

Requires pharmacists to counsel patients or their authorized representative on proper usage and operating features of the alternate epinephrine auto-injector.

Takes effect immediately upon enactment.